Immunovant (NASDAQ:IMVT) traded lower in the premarket on Wednesday after the company announced clinical trial data related ...

Immunovant and Roivant Sciences said Wednesday their rare disease drug succeeded in a final-phase study, but the duo won't seek approval.

The companies reported Wednesday that batoclimab showed improvements in myasthenia gravis patients in a Phase 3 trial.

Pivotal study in MG met primary endpoint of change from baseline in MG-ADL in AChR+ population at 12 weeks, with a 5.6 point improvement in the ...

Immunovant, Inc. (NASDAQ:IMVT) released topline results from its Phase 3 study of batoclimab in myasthenia gravis (MG) and ...

Cargo was founded by two highly acclaimed cell-therapy researchers. The company raised over $500 million to develop ...

Immunovant (IMVT) reported topline results from its Phase 3 study of batoclimab in MG and initial results from Period 1 of its Phase 2b study ...

Immunovant (Nasdaq: IMVT), a Roivant Sciences company, today reported top-line results from its Phase III study of batoclimab ...

The stock movement today reflects the market’s complex reaction to the news, balancing the positive study results with the strategic decisions regarding drug development and regulatory pathways.

NASDAQ ROIV opened at $10.66 on Monday. Roivant Sciences Ltd. has a one year low of $9.76 and a one year high of $13.06. The company has a market capitalization of $7.61 billion, a price-to ...

BASEL, Switzerland and LONDON and NEW YORK, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Roivant Sciences Ltd. (“Roivant”) today announced that the members of the Board of Directors of Arbutus Biopharma ...